GSK CEO Emma Walmsley's Pay Soars to £15.6m in Final Year
Emma Walmsley, the former chief executive of GSK, received a substantial pay increase of almost 50% in her final year leading the pharmaceutical giant, with her total remuneration reaching £15.6 million. This significant boost was primarily fueled by share bonuses, reflecting the company's robust financial performance and a notable rise in stock value.
Breakdown of the Pay Package
In 2025, Walmsley's compensation included a salary of £1.4 million, slightly higher than the previous year, and an annual bonus that increased to £3.5 million from £2.9 million in 2024. The largest component of her pay, amounting to £10 million, came from share bonuses. This was linked to a jump in GSK's share price, with the vesting price in the long-term incentive plan rising to £21.65 from £14.43 the year before.
A spokesperson for GSK emphasized that Walmsley's remuneration was justified by the company's strong performance against challenging targets. They highlighted that sales and profit grew significantly, and GSK secured five major new product approvals in the US, enhancing value for shareholders.
GSK's Financial Performance and Strategic Moves
GSK reported a 7% increase in turnover to £32.7 billion last year, driven by revenue from treatments in areas such as cancer, HIV, and asthma. However, the company anticipates a slowdown in sales growth this year. Pre-tax profit more than doubled to £7.4 billion in 2025, underscoring the financial health under Walmsley's leadership.
Walmsley, who led GSK from 2017 until handing over to Luke Miels at the start of this year, set an ambitious sales target of at least £40 billion by 2031. This goal has been reaffirmed by Miels, who has pledged to foster scientific courage and agility to develop more competitive products.
During her tenure, Walmsley orchestrated GSK's most significant corporate restructuring in two decades, including the 2022 spinoff of its consumer healthcare arm into Haleon, which houses brands like Sensodyne and Panadol. She also navigated challenges, such as a campaign by activist investor Elliott Management to oust her, while boosting research and development spending and focusing on key therapeutic areas like respiratory and cancer medicines.
Comparison with Industry Peers
In contrast, Pascal Soriot, the chief executive of rival AstraZeneca, received a 6.4% pay rise last year, bringing his total remuneration to £17.7 million. He is poised for a further increase to up to £19.6 million this year, potentially making him the UK's highest-paid chief executive once again.
Luke Miels, who succeeded Walmsley after serving as chief commercial officer, has announced several strategic deals since taking over, including a £1.6 billion acquisition of a Californian biotech firm developing treatments for severe food allergies. Miels will receive a lower salary of £1.38 million but could earn up to £16.6 million in total remuneration, including long-term share bonuses.
This pay rise for Walmsley highlights ongoing trends in executive compensation within the pharmaceutical industry, where performance-linked bonuses and share incentives play a crucial role in rewarding leadership during periods of strong corporate growth.
